A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With ER+ Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs GSK 525762 (Primary) ; Fulvestrant
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline
- 09 Oct 2017 Planned primary completion date changed from 29 Nov 2019 to 23 Apr 2020.
- 11 Sep 2017 Planned primary completion date changed from 23 Apr 2020 to 29 Nov 2019.
- 31 Aug 2017 Planned primary completion date changed from 29 Mar 2019 to 23 Apr 2020.